We assessed the HIV-positive yield of offering provider-initiated HIV testing and counselling (PITC) for TB and the costs, in Madagascar, which has a low HIV prevalence and a high TB burden.
Introduction
The 2004 WHO interim policy for collaborative TB and HIV related activities had set a threshold of 5% HIV prevalence among patients with TB for offering provider-initiated HIV testing and counselling (PITC). 1 PITC is the routine offer of HIV testing for all patients with TB at the time of TB diagnosis. In early 2012, new WHO HIV-TB policy stipulated that routine HIV testing should be offered to all patients with presumptive and diagnosed TB: the notion of thresholds was removed. 2 Madagascar is a resource-limited sub-Saharan African country with 22 million inhabitants, a relatively low HIV prevalence of 0.5% 3 and a high TB burden (annual case notification rate¼116/ 100 000). 4 Because HIV prevalence among patients with TB is only 0.9%, 5 the country has been contemplating whether PITC for patients with TB is really justified as this will require considerable additional infrastructure, human resources and materials. Madagascar has recommended PITC for patients with TB but budget requirements were not estimated. The question asked is whether available resources are being correctly allocated when balanced against health priorities.
In Madagascar, where we have been trying to implement PITC on a countrywide level since 2010, we report on the HIV positive yield and discuss the implications (mainly cost) of countrywide introduction of this intervention.
Methods
This was a cross-sectional study of routinely collected records from January 2010 to June 2011.
For reporting the HIV positive yield, we reviewed national TB programme data from all 205 TB diagnostic and treatment centres (TB centres) in Madagascar. In order to better understand the public health implications of introducing countrywide PITC, we estimated required costs. Direct cost estimates were calculated for initial costs as infrastructure and human resources, and for annual recurrent costs as materials. Cost estimates were based on standard cost tables available at the Ministry of Health. Infrastructure space within TB centres in Madagascar is limited and 'counselling guidelines' 6 stipulate minimum requirements to ensure an appropriate and conducive environment for counselling. To ensure adherence with these guidelines, full or partial rehabilitation of all centres was judged to be required. HIV testing had been introduced in 95 (46%) of TB centres that were included in this study.
Results
There were 37 596 patients registered with TB in the 205 TB centres in Madagascar. HIV testing was performed in 95 (46%) centres where 18 993 (51%) patients were registered. There were 7524 (40%) who accepted HIV testing of whom 35 (0.5%) were found positive for HIV. Table 1 shows the maximum and minimum estimated first year costs in US$ for offering countrywide PITC in Madagascar. The total cost requirements, including infrastructure, human resource and materials, ranged between about US$775 000 (minimum) to US$1 530 000 (maximum) and over 90% of them were initial costs.
Discussion
Despite scaling up HIV testing to over half of all TB centres in Madagascar, only 35 patients were found positive for HIV, giving a low HIV-positive yield of 0.5%. In this setting of low HIV prevalence, this raises questions on the justification of large investments required for implementing the new WHO recommendations of universal HIV testing for patients with TB.
First, the required initial investment to implement PITC countrywide is huge and will amount to between 19 and 30% of the annual Global Fund round 8 funds allocated to TB in Madagascar. 7 Although this is a simplistic calculation, it raises concerns around the cost-benefit of such an intervention and the possibility that S. Nagai et al.
such investments may divert resources from existing TB services. Alternative cost-saving rehabilitation techniques that are less costly and alternative less expensive infrastructure are warranted. Second, HIV testing uptake in centres offering TB registration services was low at 40%. Fear of knowing HIV sero-status, stigma and discrimination may be factors that influenced uptake. 8 A standardised, clinic-based, testing strategy that is being used in Madagascar might be less effective in low HIV prevalence settings. Alternative approaches, including community-based testing, with appropriate support services yields better dividends as has been seen in Tanzania, Zimbabwe and Thailand. 9 Our study is limited by the fact that we do not know if HIV prevalence among patients with TB in centres without HIV testing is different from that of patients with TB in centres with HIV testing. Although this could potentially influence the HIV-positive yield, it is unlikely to make a considerable difference since overall HIV prevalence in patients with TB is generally low. We also do not know the reasons why patients with TB did not accept HIV testing and this merits specific research. Finally, as rehabilitation costs will be spread over time (years), the overall cost shown in this study may taper over time. However, this does not deter from the overall message that considerable initial investment is needed for offering countrywide PITC. Our study is also focused on one geographic region and may not be widely generalisable.
In conclusion, we have raised concerns over the cost implications of the new WHO recommendation of offering universal PITC in low HIV-prevalence settings.
